Dr. Nicholas Barber, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Univ of Nebraska Medical Center, Col of Dentistry (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 405
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: Univ of Nebraska Medical Center, Col of Dentistry
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OR license MD163370 -
Internal Medicine Physician
OR license LL17367 · OR license MD163370 -
Medical Oncology Physician
OR license MD163370
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohsu Hospital and Clinics Portland, OR
- Salem Hospital Salem, OR
- Salem Health West Valley Dallas, OR
- Willamette Valley Medical Center Mcminnville, OR
- Legacy Silverton Medical Center Silverton, OR
Medical groups
- Oregon Oncology Specialists LLP (41 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 405
- Services billed
- 136,935
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 16,500 | 13 |
| Injection, pembrolizumab, 1 mg | 10,200 | 12 |
| Injection, fosaprepitant, 1 mg | 8,700 | 22 |
| Injection, denosumab, 1 mg | 4,140 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,340 | 47 |
| Injection, palonosetron hcl, 25 mcg | 870 | 30 |
| Injection, ondansetron hydrochloride, per 1 mg | 528 | 29 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 506 | 139 |
| Blood test, comprehensive group of blood chemicals | 432 | 127 |
| Injection, fluorouracil, 500 mg | 421 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Salem, OR | 113 |
| Eliquis (apixaban) Other prescribers in Salem, OR | 63 |
| Tamoxifen Citrate Other prescribers in Salem, OR | 49 |
| Oxycodone Hcl Other prescribers in Salem, OR | 48 |
| Imbruvica (ibrutinib) | 44 |
| Acyclovir Other prescribers in Salem, OR | 40 |
| Calquence (acalabrutinib maleate) | 32 |
| Lenalidomide | 29 |
| Venclexta (venetoclax) | 25 |
| Ondansetron Odt (ondansetron) Other prescribers in Salem, OR | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 18 payments worth $403 in total to this clinician.
| Daiichi Sankyo Inc. | $96.18 |
|---|---|
| Novartis Pharmaceuticals Corporation | $46.61 |
| Amgen Inc. | $32.72 |
| Tempus Ai, Inc | $30.57 |
| Pfizer Inc. | $30.34 |
| AstraZeneca Pharmaceuticals LP | $26.57 |
| Merck Sharp & Dohme LLC | $25.80 |
| GlaxoSmithKline, LLC. | $24.58 |
| Food and Beverage | $350 |
|---|---|
| Education | $52.72 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Jul 10, 2025 | Education in-kind | $32.72 |
| Aveo Pharmaceuticals, Inc. Mar 6, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.